Effect of PARP inhibitors on sensitivity of lung and breast cancer cells to trans-platinum as compared to cis-platinum.

被引：0
|
作者：
Jankovic, Radmila [1 ]
Radulovic, Sinisa [1 ]
Arandjelovic, Sandra [1 ]
Filipovic, Lana [1 ]
机构：
[1] Inst Oncol & Radiol Serbia, Dept Expt Oncol, Belgrade, Serbia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22115
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
    Garufi, Giovanna
    Palazzo, Antonella
    Paris, Ida
    Orlandi, Armando
    Cassano, Alessandra
    Tortora, Giampaolo
    Scambia, Giovanni
    Bria, Emilio
    Carbognin, Luisa
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) : 687 - 699
  • [22] Efficacy of PARP Inhibitors in Patients With BRCA1/2-related Breast Cancer with Prior Platinum Exposure: A Systematic Review and Meta-Analysis
    Marinho, Alice D.
    Pessoa, Beatriz Mella S.
    Brandao, Gabriela R.
    Da Silva, Caroliny H.
    Reis, Pedro A.
    Comini, Ana Carolina M.
    Batalini, Felipe
    CANCER RESEARCH, 2023, 83 (05)
  • [23] POLAR-SOLVENTS INCREASE THE SENSITIVITY OF CULTURED HUMAN-COLON CANCER-CELLS TO CIS-PLATINUM AND MITOMYCIN-C
    DEXTER, DL
    DEFUSCO, DJ
    MCCARTHY, K
    CALABRESI, P
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 267 - 267
  • [24] CLINICAL-TRIAL OF IPROPLATIN (CIS-DICHLORO-TRANS-DIHYDROXY-BIS-ISOPROPYLAMINE PLATINUM-IV, CHIP) IN PATIENTS WITH ADVANCED BREAST-CANCER
    CASPER, ES
    SMART, TC
    HAKES, TB
    OCHOA, M
    KAUFMAN, RJ
    INVESTIGATIONAL NEW DRUGS, 1988, 6 (02) : 87 - 91
  • [25] CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells
    Wu, Wenjing
    Zhao, Jianli
    Xiao, Jianhong
    Wu, Weijun
    Xie, Limin
    Xie, Xiaojuan
    Yang, Chaoye
    Yin, Dong
    Hu, Kaishun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 573 : 62 - 68
  • [26] New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
    Folk, Watson P.
    Kumari, Alpana
    Iwasaki, Tetsushi
    Cassimere, Erica K.
    Pyndiah, Slovenie
    Martin, Elizabeth
    Homlar, Kelly
    Sakamuro, Daitoku
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [27] Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis
    Kaneko, Masayuki
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (01) : 27 - 34
  • [28] Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses
    Mukai, Masaya
    Sato, Shinkichi
    Ninomiya, Hiromi
    Wakui, Kanako
    Komatsu, Nobukazu
    Matsui, Naruaki
    Nakamura, Masato
    Nakasaki, Hisao
    Makuuchi, Hiroyasu
    ONCOLOGY REPORTS, 2007, 18 (01) : 33 - 39
  • [29] Modulation of cis-diamminedichrolo-platinum (II) sensitivity by a thromoboxane A2 receptor antagonist in non-small cell lung cancer cell lines
    Kasahara, K
    Bando, T
    Shibata, K
    Numata, Y
    Fujimura, M
    Matsuda, T
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 127 - 127
  • [30] THE EFFECT OF A NOVEL DINUCLEAR PLATINUM COMPLEX WITH BERENIL AND 2-PICOLINE LIGANDS ON GROWTH OF HUMAN BREAST CANCER CELLS
    Bielawski, Krzysztof
    Bielawska, Anna
    Poplawska, Bozena
    Surazynski, Arkadiusz
    Czarnomysy, Robert
    ACTA POLONIAE PHARMACEUTICA, 2010, 67 (06): : 609 - 614
12345